Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Afatinib + Prednisone for Lung Cancer
Recruiting1 awardPhase 2
Dallas, Texas
This trial sought to find out if adding afatinib to prednisone treatment for advanced squamous non-small cell lung cancer (NSCLC) would be more effective than just prednisone alone.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.